Oryzon KOL Breakfast and Roadshow

New York, July 25, 2017

Key Opinion Leader Breakfast with Dr. Roger Bullock:

Epigenetic Approaches to Neurodegenerative Disorders

Hosted by: Oryzon Genomics

 

July 25, 2017

The Benjamin Hotel
125 E 50th St, New York,
NY 10022

Presentation starts at 8am
(Registration starts at 7:30am)

 

Please join Oryzon for a Key Opinion Leader Breakfast. Speaking will be Roger Bullock, MD, Chief Medical Officer of Oryzon Genomics and Carlos Buesa, PhD, Chief Operating Officer of Oryzon Genomics.

 

 Dr. Bullock will be discussing epigenetic approaches to neurodegenerative disorders. Dr. Bullock is  considered a world KOL in the space of neurodegenerative diseases. He has extensive experience as  clinical researcher, having participated in more than 70 clinical trials in Alzheimer’s disease and other CNS  conditions. Over his 30-year research career, he has authored and co-authored more than 100 peer- r  reviewed publications and book chapters in this domain and presented at numerous conferences. Recently  he has been working as a consultant for companies active in the CNS space, including Lilly and Merck.

 

 

 

 

 

 A founder of the Company in 2000, he has held the position of Chair of the Board of Directors since  then.  He earned his Ph.D. in Biochemistry from the University of Barcelona, and has completed  various programs  on finance and negotiation. He also completed the Senior Management Program  (PADE) at IESE in 2005.  In recent years, he has been a member of the board of various biotechnology  companies: ONCNOSIS  PHARMA AIE, NINFAS AIE, ORYCAMB-PROJECT AIE, GEADIG-PHARMA  AIE, NEUROTEC PHARMA,  S.L., PALOBIOFARMA, S.L. He has been a member of the Advisory  Board of NEUROSCIENCES  TECHNOLOGIES and is a member of MENDELION, S.L. He is  ORYZON’s representative on the  Governing Board of the Asociación Española de Bioempresas  (ASEBIO), of which ORYZON has been a  member since 2005, except for the period between 2009  and 2011, during which ORYZON was appointed as Vice Chair of such Governing Board. The first vice chairmanship of ASEBIO is held by Oryzon since the last elections held in December 2015 and until the next elections, which must be held before the end of 2017. Finally, he has been a member of the Board of Directors of INVEREADY SEED CAPITAL and of INVEREADY BIOTECH since September 7, 2008 and October 10, 2012, respectively.

 

Register / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

Oryzon Genomics ORY:MA
De­vel­ops per­so­n­al­ized ther­a­peu­tics for pa­tients with can­cers or neu­rode­gen­er­a­tive di­s­or­ders. The com­pany’s lead com­pound, ORY-1001, is a high­ly po­tent LS­D1 in­hibi­tor cur­rent­ly in Ph 1/2a... [more in­for­ma­tion]

Participating Trout Representatives

Benjamin Soehngen
The Trout Group, LLC

Event Contact

Thomas Hoffmann
The Trout Group, LLC

Location of the Event and Other Places